Phase 2Recruiting

Pan Tumor Rollover Study

Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer Therapies

Sponsor
Bristol-Myers Squibb (Industry)
Enrollment
1,500 planned
Conditions
Cancer
Interventions
Nivolumab; Ipilimumab; Cabozantinib; Trametinib; Relatlimab; Nivolumab + Relatlimab; Capecitabine; Bevacizumab; Temozolomide; Rucaparib; Daratumumab; Regorafinib
Ages
adults, older adults
Registry
NCT03899155, EUCTR2018-004362-34

Full record on ClinicalTrials.gov

From the registry

Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types.

Primary outcomes

  • Incidence of Adverse Events (AEs)
  • Incidence of drug related AEs
  • Incidence of AEs leading to Discontinuation
  • Incidence of Serious Adverse Events (SAEs)

History

  1. Primary completion expected

  2. Last registry update

  3. Started

  4. Registered